GLP-2TR (Tirzepatide)
10mg
Dual GIP and GLP-1 receptor agonist for metabolic research.
Research Profile
About GLP-2TR (Tirzepatide)
Tirzepatide (GLP-2TR) is a synthetic dual agonist that simultaneously targets the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By combining two incretin pathways in a single peptide, it produces a pharmacological profile distinct from selective GLP-1 agonists.
It is one of the most extensively studied incretin peptides in metabolic research and is frequently used as a reference compound in glucose-regulation and body-weight models. Provided lyophilized for laboratory research use only.
Mechanism of Action
Dual activation of the GIP and GLP-1 receptors is studied for its combined effects on glucose-dependent insulin release, glucagon modulation, gastric emptying, and central satiety signaling, with the GIP component thought to complement and amplify GLP-1 activity.
Research Applications
- Glycemic-control and insulin-sensitivity models
- Body-weight and metabolic research
- Incretin receptor signaling studies
- Comparative dual- vs single-agonist research
Provided for educational and research context only. GLP-2TR (Tirzepatide) is sold strictly for in-vitro laboratory and research use — it is not a drug, supplement, or medical product, is not intended to diagnose, treat, cure, or prevent any disease, and is not for human or veterinary use.
Support
Frequently Asked Questions
Everything you need to know about this product and your order.
